Advancing real-time monitoring of AAV vector processes

PODCAST INTERVIEW with:Rachel LegmannDirector of Technology, Gene Therapy Rachel has more than 25 years experience in the field scalable biologics and gene therapy manufacturing therapeutic products, viral vectors proteins for biologics. She completed her Ph.D. Food Engineering Bio-technology at Technion-Israel Institute Israel. joined Repligen 2021 as a subject matter expert leading global organiza-tion helping customers achieve their technical operational objectives vector-based therapeutics vaccines with focus on processes including upstream, downstream, analytics scalability. In addi-tion to supporting building high level networks, is sup-porting various internal cross-functional activities external collaborations. Prior joining Repligen, held several scientific leadership roles Microbiology Molecular Genetics department Harvard Medical School, CRO SBH Sciences, Sea-horse Biosciences part Agilent, CDMO Goodwin Biotechnology Pall Corp Danaher. and Joe FerraioloJoe FerraioloAssociate Director Bioanalytics, Repligen Joe Associate Bioanalytics Repligen. He charge Bioana-lytics Applications related SoloVPE Variable Pathlength UV solu-tion. been company 20 years, over 10 development validation analytical applications. specializes analysis leads commercialization high-value products flexible solutions that address critical steps production biologic drugs, solutions, monoclonal antibodies.